Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive [177Lu]Lu-PSMA-597 with ADT and ARPI for metastatic hormone-sensitive prostate cancer
ACTRN12626000034336Phase 2Not yet recruiting
- Sponsor
- St Vincent's Hospital Sydney
- Start
- Jun 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 177Lu-PSMA-597 in prostate cancer (PCa), sponsored by St Vincent's Hospital Sydney. Primary endpoint: PSA response at 6 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
177Lu-PSMA-597
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12626000034336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000034336.